New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 3, 2013
08:12 EDTALNYAlnylam, collaborators publish ALN-PCS clinical trial results
Alnylam Pharmaceuticals announced the publication in The Lancet of complete study results from a Phase I trial with ALN-PCS. The paper reports the results of a study evaluating single intravenous dose administration of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins. Specifically, ALN-PCS administration resulted in a rapid, dose-dependent reduction in plasma PCSK9 of up to 84% relative to baseline and placebo, with a corresponding reduction in serum levels of low-density lipoprotein cholesterol, a clinically validated endpoint, of up to 57% relative to baseline and placebo. The knockdown of PCSK9 and lowering of LDL-C were also found to be durable, with effects lasting for weeks after a single dose. This new paper documents the first human proof of concept for an RNAi therapeutic impacting a clinically validated endpoint.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
06:02 EDTALNYAlnylam price target lowered to $102 from $184 at Piper Jaffray
Subscribe for More Information
February 11, 2016
16:02 EDTALNYAlnylam reports Q4 EPS ($1.07), consensus (96c)
Subscribe for More Information
February 2, 2016
08:36 EDTALNYPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
08:03 EDTALNYAlnylam completes enrollment in APOLLO Phase 3 study with Patisiran
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use